Format

Send to:

Choose Destination
See comment in PubMed Commons below
Therapie. 2010 Nov-Dec;65(6):533-41. Epub 2010 Dec 23.

Safety review: squalene and thimerosal in vaccines.

Author information

  • 1Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universités d'Aix-Marseille I, II et III, UMR-CNRS 6264, Laboratoire Chimie Provence, Marseille, France.

Abstract

Few studies show the reluctance of the people to get vaccinated against A (H1N1) influenza for fear of side effects of squalene (MF59, AS03, AF03) and thimerosal. The aim of this paper is to assess the safety in using these adjuvants and preservative reviewing data of clinical trials relative to which formulation includes these compounds. In the current state of knowledge, these vaccines have proved to be effective even though they more frequently give local adverse events than non-adjuvanted influenza vaccines. Systemic side effects are generally not serious. In the studies, adjuvanted vaccines do not increase neither the risk of Guillain Barre syndrome nor auto-immune diseases. There is no convincing evidence that exposure to thimerosal in vaccines had any deletorious effect on physiological outcome.

© 2010 Société Française de Pharmacologie et de Thérapeutique.

PMID:
21176760
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for EDP Sciences
    Loading ...
    Write to the Help Desk